Business
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in
About this update from Madrigal Pharmaceuticals, Inc.
[{"type":"text","content":"CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: Jefferies Global Healthcare Conference in LondonThursday, Nov. 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET)The presentation will be webcast live and may be accessed here. 8th Annual Evercore Healthcare ConferenceTuesday, Dec. 2, 2025 at 4:15 P.M. ETThe presentation will be webcast live and may be accessed here. Piper Sandler 37th Annual Healthcare ConferenceWednesday, Dec. 3, 2025 at 1:30 P.M. ETThe presentation will be webcast live and may be accessed here. The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page. About MadrigalMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com. Investor Contact Tina Ventura, [email protected] Media ContactChristopher Frates, [email protected] \nSource: Madrigal Pharmaceuticals, Inc.","length":5058,"tagName":"div"}]